Key result
NOAC therapy was independently associated with increased time to surgery beyond 36 hours (p=0.001) in hip fracture patients, whereas warfarin therapy was not.
Why the study?
Neck of femur fractures are common in anticoagulated elderly patients, and it was unknown whether admission on warfarin or NOAC therapy increased the risk of operative delay, prolonged length of stay, or increased mortality.
Does NOAC or warfarin therapy delay surgery, increase length of stay, or reduce survival in hip fracture patients?
Cohort (n=845)
No
Does NOAC or warfarin therapy delay surgery, increase length of stay, or reduce survival in hip fracture patients?
p-value: p=0.001
In hip fracture patients, pre-admission NOAC therapy is associated with delayed surgery beyond 36 hours, highlighting the need for specific perioperative management protocols.
No takes yet. Share an insight, caveat, or question.
Supports targeted NOAC perioperative protocols in hip fracture; leaves open effects on survival or length of stay.
Hourston et al. (2019) conducted a cohort in Hip fracture (n=845). NOAC therapy vs. Warfarin therapy or no anticoagulation was evaluated on Time to surgery beyond 36 hours (p=0.001). NOAC therapy was independently associated with increased time to surgery beyond 36 hours (p=0.001) in hip fracture patients, whereas warfarin therapy was not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: